Anaphylaxis has occurred with MEPSEVII administration, as early as the first dose, therefore appropriate medical support shouldbe readilyavailable when MEPSEVII is administered.
Closely observe patients during and for 60 minutes after MEPSEVII infusion.
Immediately discontinue the MEPSEVII infusion if the patient experiences anaphylaxis